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Objectives: Despite the American Heart Association’s interest in research on 
the determinants of health-related quality of life (HRQoL) among Acute Coronary 
Syndrome (ACS) survivors, little is known about trajectories of HRQoL post-ACS. 
We sought to identify such longitudinal patterns, and their predictors, over the 
6 months post-ACS discharge. MethOds: We used data from the Transitions, 
Risks, and Actions in Coronary Events – Center for Cardiovascular Outcomes and 
Education (TRACE-CORE) prospective cohort of patients hospitalized with ACS. 
HRQoL was measured using the Seattle Angina Questionnaire (SAQ) at the index 
hospitalization and at 1-, 3 -, and 6-months post-discharge. The quality of life 
subscore of the SAQ ranges 1-100 with higher scores indicating better HRQoL. We 
used trajectory analysis to identify subgroups of patients with distinctive 6-month 
post-discharge HRQoL patterns, and predictors of different trajectories. Results: 
Participants (N= 920) had mean age 63 (SD 11) years, 34% were female, and 
83% non-Hispanic white. We identified 3 HRQoL trajectories (FAIR, GOOD, and 
EXCELLENT HRQoL) consisting of 12.1%, 53.8% and 34.1% of participants, respec-
tively: FAIR (baseline average HRQoL = 38.8, and remaining low over the 6-month 
follow-up); GOOD (baseline average = 62.6 and increasing modestly over time); 
and, EXCELLENT (baseline average = 87.0 and remaining high). With FAIR HRQoL 
as the referent, we found that older age predicted better HRQoL (OR per year for 
GOOD = 1.09 and for EXCELLENT = 1.18) as did non-Hsipanic white race/ethnic-
ity (OR for GOOD = 3.01; for EXCELLENT = 4.21) and male sex (OR for GOOD= 1.17 
p= 0.56, for EXCELLENT = 2.57). [All p < 0.05, except as noted.] cOnclusiOns: On 
average, HRQoL was relatively stable over time, and no trajectories with decreasing 
HRQoL were found. Early HRQoL scores could direct resources to improve HRQoL 
over the first 6 months post-ACS.
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Objectives: Since 2005, the American Diabetes Association’s (ADA’s) Standards 
of Medical Care in Diabetes have recommended that elderly diabetic patients 
with overt cardiovascular disease (CVD) or CVD risk factors should take statins 
to manage lipid levels. The objectives of this study were to 1) provide national 
estimates of statin utilization, and 2) identify predictors of statin use in elderly 
Medicare beneficiaries with diabetes to whom the ADA’s Standards of Medical Care 
apply. MethOds: This study was a pooled cross-sectional study of the Medicare 
Current Beneficiaries Survey (MCBS) from 2006 to 2010. Sampling weights were 
applied to generate national estimates. Weighted logistic regression was performed 
to identify predicators of statin use. Results: Among 8,539 person-years of elderly 
diabetic patients, 8,115 (94.69%, weighted percentage) were eligible for statin therapy 
according to the ADA’s Standards of Medical Care. In 2006, 2007, 2008, 2009, and 2010, 
55.27%, 53.30%, 53.23%, 57.86%, and 60.70% of eligible diabetics used statins, respec-
tively. Predictors of non-use of statin included: being non-Hispanic black (odds ratio 
[OR]: 0.69; 95% confidence interval [CI]: 0.56-0.84), living in non-metropolitan areas 
(OR: 0.78; 95% CI: 0.69-0.88), being underweight, with a body mass index of 18.5 or 
under, (OR: 0.27; 95% CI: 0.13-0.54), having one or more comorbidities in addition to 
CVD (OR: 0.81; 95% CI: 0.68-0.95), and having CVD risk factors (OR: 0.59; 95% CI: 0.51-
0.67). cOnclusiOns: A 10% increase in statin use was observed among diabetic 
patients who satisfied ADA’s criteria for statin use between 2006 and 2010. Still, 
approximately 40% of eligible individuals with diabetes were not taking statins in 
2010. For elderly Medicare beneficiaries with diabetes, healthcare providers should 
be aware of patient factors associated with statin non-use and provide interventions 
to improve prescribing patterns and patient adherence.
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bAckgROund: Obesity is a chronic condition and its clinical and economic conse-
quences are very concerning. Obesity and its co-morbidities were associated with 
USD 2.1 billion annually costs in the Brazilian Public Health System. According to 
a National Survey there are 22 million people in Brazil with BMI > 30kg/m2. Also 
there are 13.5 million diabetic people, many of them being obese Objectives: To 
describe epidemiology, treatment patterns, resource use and associated costs of 
morbid obese patients in the list, waiting to receive surgical treatment for surgery 
in order to quantify the clinic and economic burden of not providing surgical treat-
ment to eligible patients MethOds: Non-interventional, single center, retrospec-
tive cohort with medical chart review of 300 patients who met eligibility criteria, 
having their registry data extracted and outcomes followed-up for up to 12-months 
post-bariatric-surgery Results: The mean time in the waiting list was 751.76 days. 
BMI mean at baseline was 46,53 kg/m2 (95% CI 45,67-47,39); 43,78 kg/m2 (95% CI 
42,98-44,59) at surgery and 30,91 kg/m2 (95% CI 30,29-31,55) at 12-months follow-up. 
195(65%) of patients presented hypertension at baseline, which 92,8% presented 
improvement/resolution 12-months after surgery. 70(23,3%) presented dyslipidemia, 
with resolution of 94,3% after 12-months. 55(18,33%) presented diabetes, with res-
olution of 94,3% after 12-months. 37 (12,33%) patients increased BMI during the 
wait list., these patients presented lower comorbidities resolution rates compared 
to patients who maintained or reduced their BMI in the wait list cOnclusiOns: 
Analysis demonstrated high comorbidities resolution rates after 12 months of follow 
for age, sex, blood pressure (BP) stage and history of stroke, we found that the utili-
ties in older patients were lower than those of the younger groups, and statistically 
significantly differing if compared the extremes of youngest and oldest groups 
were considered (p= 0.03). Utility in males was higher than in females (p= 0.002). 
Patients with a history of stroke exhibited lower utility than patients without such 
history, although not statistically significant (p= 0.73). Patients with more than 
3 comorbidities had lower utilities than patients without comorbidity (p= 0.01). 
Statistically in significantly relatively higher BP was associated with lower utility 
at 0.734, 0.726 or 0.712 in the groups with target BP, stage 1 and 2, respectively (p= 
0.422). cOnclusiOns: Mean utility was estimated at 0.72 in hypertensive patients 
in Vietnam. In contrast to BP staging and history of stroke, gender was found as a 
statistically significant predictor of utility. In addition, patients who experience 
more than 3 comorbidities or older than 70 had statistically significant lower utili-
ties.
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Objectives: There is limited information on drivers of utilities in patients with 
chronic heart failure (CHF). We analyzed determinants of utility in CHF and driv-
ers of change over one year in a large sample from clinical practice. MethOds: 
We included 5334 patients from the Swedish Heart Failure Registry with EQ-5D 
information available following inpatient or outpatient care during 2008 to 2010; 
3495 had 1-year follow-up data. We applied ordinary least squares (OLS) and two-
part models for utility at inclusion, OLS regression for change over one year, all 
with robust standard errors. We assessed predictive accuracy of both models using 
cross-validation. Results: Mean age was 73 years, 65% were male, 19% had a left 
ventricular ejection fraction ≥ 50%, 23% 40-49%, 27% 30-39%, and 31% < 30%. For both 
models, utility at inclusion was negatively affected by female gender, increasing 
age, increasing New York Heart Association (NYHA) class, preserved left ventricular 
ejection fraction, lung disease, diabetes, and use of nitrates, antiplatelets or diuret-
ics. Higher systolic blood pressure and haemoglobin levels and use of angiotensin 
converting enzyme inhibitors/angiotensin receptor blockers or beta-blockers were 
associated with increased utility. A significant interaction between age category 
and functional class indicated that patients in the youngest age group are more 
severely affected by worsening functional status than older patients. The OLS model 
performed slightly better than the two-part model on a population level and for 
capturing utility ranges. Change in utility over one year was influenced by age, 
gender, disease duration, and (measured at inclusion) NYHA class, blood pressure, 
ischemic heart disease, lung disease, angiotensin converting enzyme inhibitors/
angiotensin receptor blockers and antiplatelets. cOnclusiOns: Utilities in CHF 
and their change over time are influenced by diverse demographic and clinical 
factors. Our findings can be used to target clinical interventions and for economic 
evaluations of new therapies.
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Objectives: The TCM-SAQ was a valid and reliable syndrome-specific instruction 
to assess quality of life (QoL) for angina treated by traditional Chinese medicine. 
However, its ability to detect change has not been discussed. This study was aimed 
to investigate the ability of detecting change over time of the TCM-SAQ. MethOds: 
The data is performed from an Random Clinical Trail. Patient diagnosed with angina 
pectoris were enrolled in ten Chinese medical hospitals in the northeast of China, 
from June, 2011 to May, 2012. All enrolled patients were treated by Chinese herbs 
combined with aspirin and Lipitor for 8 weeks; nitrates were used to release angina 
attack. Angina symptoms (frequency, duration, pain degree) were used to assess the 
therapeutic efficiency; lower scores represent better angina conditions. TCM-SAQ 
was tested at the enrollment and 8th weeks of the treatment, higher scores means 
better quality of life. Results: Analysis is based on 240 patients (age 60±7years; 
111 male, 52%). The disease history is 3.5±3.5 years. Seventy-nine (32.9%) patients 
have at least one comorbidity. The average angina attack times per week before 
the treatment is 6.28, and 2.36 after eight weeks’ treatment, which declined 3.97 
times; the average angina attack duration is 5.73 before, and 2.56 after, and angina 
score declined 4.1 after the treatment. TCM-SAQ shows a significant improved of 
QoL in each domain as well as the angina condition changes (P= 0.000). Of all those 
patients, 64 patient’s (26.7%) angina condition remained unchanged, and 176 (73.3%) 
improved. Therapeutic effective patients show a better QoL than invalid patients. 
TCM-SAQ can detect the differences between effective and invalid patients in 
domains(p= 0.000). cOnclusiOns: The TCM-SAQ has a good ability to detect clini-
cal change over time in individuals, and it also can detect the differences between 
known groups. In the future, we need to determine the minimal clinic differences 
of TCM-SAQ.
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matched and analyzed to see if there any trend and relation between the num-
ber of drugs added in the NHF and the percentage of deaths listed for each dis-
ease. Results: The NHF has drugs for every disease evaluated. In the period 
analyzed, the number of drugs for DM has increased from 18 to 24. In the case of 
IHD, the number has also grown from 20 to 32. For CD there has been also an addition 
from 10 to 13. The drugs for ALD is the same in each year (only one drug). At last, 
for COPD the number has change from 35 to 36 drugs. Comparing with the number 
of deaths, the IHD is the disease with the biggest increased of deaths (22%), then 
the DM with 12%, COPD 11%, ALD 4%, and CD 3%. cOnclusiOns: Although there 
have been added new drugs prescribed for the diseases that caused the deaths of 
most population in the NHF, this quantity is not comparable with the growing of 
deaths observed in each disease.
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Objectives: As reported by the Centers for Disease Control and Prevention (CDC) 
more than half of adults with high blood cholesterol level did not receive any treat-
ment. Untreated high blood cholesterol can lead to coronary heart diseases. The 
primary objective of this study is to describe and contrast the socioeconomic factors 
between treated and untreated patients with hyperlipidemia. Secondary objective is 
to compare prescribed medicines expenditures between the two groups. MethOds: 
This study conducted cross-sectional secondary data analyses using 2012 Medical 
Expenditures Panel Survey (MEPS). Study subjects consisted of US civilian, non-
institutionalized adults diagnosed with high blood cholesterol. Series of statistical 
comparisons on socioeconomic factors, and prescribed medicines expenditures and 
utilizations between hyperlipidemia patients with any FDA-approved lipid lowering 
agent and hyperlipidemia patients without lipid lowering agents. The Andersen 
Behavioral Model was applied to define the socioeconomic factors. SAS 9.3 statistical 
software was used for all analyses including sample weights and standard errors 
adjustments. Results: Approximately 19 million patients had high blood choles-
terol related events in 2012. The average age of treatment group was older than the 
average age of no-treatment group, 64 and 62 years old respectively, (p< 0.001). 95% 
of hyperlipidemia patients with high income had treatment, on the contrary, 93% 
of hyperlipidemia patients with near poor income had treatment. The average total 
prescription expenditures for patients with treatment was higher than patients 
without treatment, $3032 and $2509 respectively, (p< 0.001). cOnclusiOns: The 
study findings showed substantial number of hyperlipidemia patients without 
treatment. Also there were some socioeconomic differences between treatment 
group and no-treatment group. Further research is recommended to understand 
the complex role of socioeconomic factors in hyperlipidemia therapy to make more 
effective policies and programs designed to improve treatment for one of the major 
chronic conditions in the United States.
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Objectives: To analyze the use of statins in 90 days after hemodialysis among the 
prior-users. MethOds: This retrospective cohort study used the 1997-2008 National 
Health Insurance Research Data to analyze the use of statins among prior users 
aged 20 years or older after they started maintenance hemodialysis. These prior 
users were prescribed with statins at least once in 180 days prior to hemodialysis. 
Discontinuation of statin prescription was defined when there was no prescrip-
tion records in the following 90 days, and the date of discontinuation was coded 
as the last date of prescription plus medication period. We used Cox proportional 
hazard model to examine the potential factors attributable to the discontinuation 
of statin prescription. We also analyze the pattern of re-use of statins after one 
year. Results: Among 8982 statin users, 2079 patients continued to use statins 
after hemodialysis. In 90 days after hemodialysis, the average medication days 
among the continued users was 65.8 days. Among the discontinued users, 65% 
stopped using statins in the 90 days before hemodialysis; 8.7% of them started 
using statins in the first 6 months and 19% started in the first year again. Analysis 
of the Cox proportional hazard model showed that being male(HR 1.10, 95% CI 1.05, 
1.15) and no statin prescription in 90 days before hemodialysis(HR 1.78ï¿½, 95% 
CI 1.68, 1.87) were attributable to the discontinuation of statins in 90 days after 
hemodialysis; those with coronary heart disease(HR 0.93ï¿½, 95% CI 0.89, 0.98) and 
peripheral vascular disease(HR 0.87ï¿½, 95% CI 0.79, 0.96) tended to continue using 
statins. cOnclusiOns: Most statin users stopped using statins after hemodialysis. 
In fact, most of them stopped using statins in the 90 days before hemodialysis. 
Subjects who were female and with medical history of cardiovascular diseases 
or peripheral vascular disease were more likely to continue using of statins after 
hemodialysis.
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Objectives: Cardiovascular diseases (CVD) are the major health problem in con-
temporary world, particularly in developing countries. The impact of the costs 
of Agents acting on RAS to the healthcare budgets is relatively high. It is impor-
tant to establish the use of cheaper generic and to reduce the healthcare costs. 
The aim of our study was to identify and analyze changes in the usage of these 
up and significant reduction on medications consumption. Patients who increased 
BMI during the wait list presented lower rates of comorbidities resolution compared 
to patients who maintained or reduced their BMI in the wait list. Based on the out-
comes presented, bariatric surgery is a procedure that can help the Brazilian health 
system to treat obesity and its co-morbidities
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Objectives: The efficacy of warfarin for reducing stroke risk is influenced by its 
time-in-therapeutic range (TTR, i.e. time patients spend having an international 
normalized prothrombin time ratio, INR= 2-3). This study evaluated warfarin TTRs 
among nonvalvular atrial fibrillation (NVAF) patients treated in an integrated 
healthcare delivery system (IDHS) setting. MethOds: Patients with NVAF, war-
farin therapy, and INR measurements were identified from an electronic medical 
record database (1/1/2004-8/31/2013). NVAF patients were required to have ≥ 6 INR 
test values to ensure chronic warfarin therapy. Warfarin TTRs were determined by 
the modified Rosendaal method. INR values collected during hospitalization stays 
were not included in the TTR calculation, since they may not be indicative of poor 
INR control. Patient characteristics during a 12-month follow-up period after the 
first INR test were evaluated. Results: Among the NVAF study population, greater 
than half (54%, n= 1,595) had a low TTR (< 60%) and 46% (n= 1,356) had a high TTR 
(≥ 60%). Mean ages of patients with low and high TTR were 71.1 and 72.2 years, 
respectively. Charlson Comorbidity Index (2.9 vs. 2.3, p< 0.001) and CHADS2 (2.2 
vs. 2.0, p< 0.001) scores were higher for NVAF patients with low TTR vs. high TTR. 
Among NVAF patients with low TTR, 79% had a warfarin TTR < 55% and 21% had a 
TTR of 55-60% during the follow-up period. Among NVAF patients with high TTR, 
24%, 41%, and 35% had warfarin TTRs of 60-64%, of 65-74%, and ≥ 75%, respectively 
during the follow-up period. Among NVAF patients with low and high TTR, 45% 
and 73% of them spent time in the warfarin therapeutic range (INR between 2-3), 
respectively. cOnclusiOns: Based on a conservative approach to evaluate the 
warfarin TTR, our results indicate that it still remains very challenging in a con-
temporary real-world setting to achieve consistently good levels for the majority 
of our NVAF patients.
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Objectives: A key goal for managed care organizations is to improve patient 
health outcomes and reduce costs. One strategy involves increasing medication 
adherence among patients with chronic diseases. The Kentucky Department for 
Medicaid Services contracted with three managed care organizations in November 
2011 to transition the state’s traditional fee-for-service Medicaid patients into 
capitated managed care. The purpose of this study is to determine differences in 
medication adherence before and after the switch from fee-for-service to managed 
care for Medicaid patients in Kentucky with essential hypertension between 2010 
and 2012. MethOds: The retrospective cohort study sample will be drawn from 
a database of Kentucky Medicaid patient (age 18-64) medical and prescription 
claims between 2010 and 2012. The University of Kentucky Internal Review Board 
approved the study. The study will include descriptive statistics of the medica-
tion possession ratio (MPR) and control variables including patient demographics, 
type of antihypertensive, and comorbidities. Bivariate analyses will measure the 
effect of each variable on the change in MPR as a result of the switch. Multivariate 
analysis will be a difference-in-difference regression model, measuring the pre and 
post differences in MPR due to the introduction of managed care. Results: Initial 
data collected indicate that average MPR decreased by about 13 percentage points, 
regardless of medication class, after Medicaid managed care in Kentucky took 
effect, with other factors held constant. A 13-percentage point decrease in MPR 
corresponds to about 45 fewer days of medication possession. cOnclusiOns: 
Results are preliminary, but indicate a need to address the efficacy of Medicaid 
managed care on adherence to antihypertensives in Kentucky. Additional studies 
should be conducted with data from 2013 to ensure confounding due to transi-
tional issues is eliminated. Future studies will examine the effect of Medicaid 
managed care on adherence in hyperlipidemia, diabetes, asthma, and mental 
health disorders.
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Objectives: The aim of this work is to demonstrate if the National Health 
Formulary (NHF) has included drugs related to the principal causes of death in the 
last 5 years (Diabetes Mellitus (DM), Ischemic Heart Diseases (IHD), Cerebrovascular 
Diseases (CD), Alcoholic Liver Diseases (ALD) and Chronic Obstructive Pulmonary 
Disease (COPD)), and if the number of the drugs added each year is in accordance 
with the increase number of deaths per disease. MethOds: A search in the National 
Institute of Statistics and Geography and the National System of Information on 
Health was done, from 2009 to 2013, related to the 5 principal causes of death in 
Mexico. Then, there were counted and analyzed the number of drugs prescribed 
for each disease studied in the last 5 NHF editions. Finally, all data obtained was 
